However, it is also arguable whether there is a real need to develop single-gene targeted agents considering that the growth and survival of cancer cells are often driven by aberrant expression of a group of related genes that are often co-regulated by common transcription factors such as RUNX2 or p53 [40]. This evidence concerns the gene TP53 and cancer.